Conclusion of an exclusive licensing and development agreement for Solucin® Targeted Radionuclide Therapy (TRT) in South Korea.

Read more

ITM announced today the appointment of Michael Lee-Chin to its supervisory board, starting May 23, 2019.

Read more

ITM announced today the lease of a new building in Neufahrn near Munich to increase the production capacity of no-carrier-added (n.c.a.) Lutetium-177…

Read more

ITM and UIH to collaborate in marketing and sales of ITM and UIH imaging and related products to clinical customers in China and worldwide.

Read more

ITM Isotopen Technologien München AG (ITM), a specialized group of radiopharmaceutical companies, announced today that it has received the Pharma…

Read more

The companies to combine their technologies to develop novel theranostic radiopharmaceuticals.

Merck to supply folate derivatives for the preparation…

Read more

Houston (TX, USA) and Garching (Germany), July 26, 2018 – RadioMedix Inc. and ITM Isotopen Technologien München (ITM), a group of specialized…

Read more

Strategic Partnership supports Commercialization beyond ongoing Phase 3 VISION Trial of 177Lu-PSMA-617

Read more

Bruce Power to secure global supply of no-carrier-added Lutetium-177 through 2064.

ITM to achieve new scalability of n.c.a Lutetium-177…

Read more

Recruitment in the U.S. for the COMPETE trial to begin shortly.

Solucin® studied as a first-line therapy.

Exclusively-produced…

Read more